Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DHQI14
|
|||
| Drug Name |
SAR445088
|
|||
| Indication | Chronic inflammatory demyelinating polyneuropathy [ICD-11: 8C01.3] | Phase 2 | [1] | |
| Immune thrombocytopenia [ICD-11: 3B64] | Phase 2 | [2] | ||
| Autoimmune haemolytic anaemia [ICD-11: 3A20] | Phase 1 | [3] | ||
| Cold agglutinin disease [ICD-11: 3A20.1] | Phase 1 | [4] | ||
| Company |
Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement C1s component (C1S) | Target Info | Inhibitor | [5] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Pertussis | ||||
| Staphylococcus aureus infection | ||||
| Systemic lupus erythematosus | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| WikiPathways | Complement and Coagulation Cascades | |||
| Complement Activation, Classical Pathway | ||||
| Human Complement System | ||||
| Complement cascade | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04658472) A Phase 2, Multicenter, Open-label, Non-randomized, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of SAR445088 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04669600) A Multicenter, Phase 2a, Open-label, Non-randomized Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP). U.S.National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT04802057) An Open-label, Long-term, Safety and Tolerability Study of SAR445088 in Participants With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088. U.S.National Institutes of Health. | |||
| REF 4 | ClinicalTrials.gov (NCT04269551) A Multicenter, Phase 1b, Open Label, Nonrandomized, Single Dose Study Evaluating the Safety, Tolerability and Activity of BIVV020 in Adults With Cold Agglutinin Disease. U.S.National Institutes of Health. | |||
| REF 5 | First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor. Clin Transl Sci. 2023 Apr;16(4):673-685. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.